C
CXL Ophthalmics
A clinical-stage company developing a minimally-invasive treatment for keratoconus
About CXL Ophthalmics
CXL Ophthalmics, which rebranded as Epion Therapeutics in July 2023, is a clinical-stage biopharmaceutical company focused on developing treatments for ectatic corneal diseases. The company was founded in 2012 and is headquartered in Burlington, Massachusetts. Michael D. Webb serves as the President and Chief Executive Officer, bringing over 25 years of entrepreneurial experience in healthcare and life sciences, specializing in early-stage companies. The company's Chief Medical Officer is Dr. Michael Belin, and its Chief Scientific Officer is Dr. Roy Rubinfeld.
The company is centered on the development of its proprietary EpiSmart system, a drug-device combination for performing minimally-invasive, epithelium-on (epi-on) corneal cross-linking (CXL). This procedure is designed to treat keratoconus, a progressive eye disease where the cornea thins and bulges into a cone-like shape, causing distorted vision. Unlike the traditional FDA-approved "epi-off" method that requires the surgical removal of the cornea's outer layer (the epithelium), EpiSmart's approach preserves this layer. This key difference aims to reduce patient discomfort, lower the risk of infection, and significantly shorten recovery time, with patients potentially returning to normal activities within a couple of days. The business model revolves around gaining FDA approval for the EpiSmart system and commercializing it for use by ophthalmologists and eye care professionals. The target market includes millions of patients globally who suffer from keratoconus and could benefit from an earlier, less invasive intervention.
The EpiSmart system consists of a riboflavin drug formulation (RiboStat) and a UVA light delivery device. The procedure involves applying the proprietary riboflavin solution, which is designed to penetrate the intact epithelium, followed by a controlled application of UVA light to strengthen the collagen fibers within the cornea. A significant feature is the potential for simultaneous bilateral treatment, allowing both eyes to be treated at the same time. In September 2022, the company secured a $32 million Series A funding round led by AXA IM Alts to advance the EpiSmart system through Phase 3 clinical trials toward a New Drug Application with the FDA. Results from its extensive Phase 2 trial, the largest of its kind with over 2,200 subjects, showed promising safety and efficacy, with 80% of patients maintaining or improving their corrected vision 12 months post-operation and experiencing fewer adverse events compared to the epi-off standard of care.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2022 | $32M | $128M | AXA Investment Managers | ↗ |
Growth signals
Latest recorded traffic for CXL Ophthalmics is 240 monthly website visits, up 140% over the last three months. CXL Ophthalmics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CXL Ophthalmics in the Burlington ecosystem
The CXL Ophthalmics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
AXA Investment Managers
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CXL Ophthalmics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CXL Ophthalmics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








